Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone

British Journal of Cancer

Volumn 112, Issue 10, 2015, Pages 1717-1724

  Salvi, S ^a   Casadio, V ^a   Conteduca, V ^a   Burgio, S L ^a   Menna, C ^a   Bianchi, E ^a   Rossi, L ^a   Carretta, E ^a   Masini, C ^a   Amadori, D ^a   Calistri, D ^a   Attard, G ^b   De Giorgi, U ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

abiraterone; androgen receptor; castration resistant prostate cancer; circulating cell free DNA; CYP17A1

Indexed keywords

ABIRATERONE ACETATE; ANDROGEN RECEPTOR; CYTOCHROME P450 17; CYTOCHROME P450 17A1; DNA; PREDNISONE; UNCLASSIFIED DRUG; ABIRATERONE; ANDROSTANE DERIVATIVE; AR PROTEIN, HUMAN; CYP17A1 PROTEIN, HUMAN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PROSTATE SPECIFIC ANTIGEN; STEROID 17ALPHA MONOOXYGENASE;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CIRCULATING TUMOR CELL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; COPY NUMBER VARIATION; DIARRHEA; GENE IDENTIFICATION; GENE LOSS; GENETIC ANALYSIS; GENETIC ASSOCIATION; HEART FAILURE; HUMAN; HYPERTRANSAMINASEMIA; KIDNEY FAILURE; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; MIDDLE AGED; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROSTENES; CASE-CONTROL STUDIES; DISEASE-FREE SURVIVAL; DNA; DNA COPY NUMBER VARIATIONS; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN; RETROSPECTIVE STUDIES; STEROID 17-ALPHA-HYDROXYLASE;

EID: 84929292191     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.128     Document Type: Article

References (30)

1. Antonarakis ES, Lu C, Wang HN, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J. (2014). AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 371(11): 1028-1038
2. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26(28): 4563-4571
3. Bishr M, Saad F. (2013). Overview of the latest treatments for castrationresistant prostate cancer. Nat Rev Urol 10(9): 522-528
4. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. (2011). Intratumoral de novo steroid synthesis activates androgen receptor in castrationresistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71(20): 6503-6513
5. Carreira S, Romanel A, Goodall J, Grist E, Ferraldeschi R, Miranda S, Prandi D, Lorente D, Frenel JS, Pezaro C, Omlin A, Rodrigues DN, Flohr P, Tunariu N, de Bono JS, Demichelis F, Attard G. (2014). Tumor clone dynamics in lethal prostate cancer. Sci Transl Med 6(254): 254ra125
6. Crowley E, Di Nicolantonio F, Loupakis F, Bardelli A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 10(8): 472-484
7. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman Jr. OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. (2011). Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364(21): 1995-2005
8. De Giorgi U, Caroli P, Burgio SL, Menna C, Conteduca V, Bianchi E, Fabbri F, Carretta E, Amadori D, Paganelli G, Matteucci F. (2014). Early outcome prediction on 18F-fluorocholine PET/CT in metastatic castration-resistant prostate cancer patients treated with abiraterone. Oncotarget 5(23): 12448-12458
9. Edwards J, Krishna NS, Grigor KM, Bartlett JM. (2003). Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 89(3): 552-556
10. Ellinger J, Müller SC, Stadler TC, Jung A, von Ruecker A, Bastian PJ. (2011). The role of cell-free circulating DNA in the diagnosis and prognosis of prostate cancer. Urol Oncol 29(2): 124-129
11. Ferraldeschi R, Sharifi N, Auchus RJ, Attard G. (2013). Molecular Pathways: Inhibiting steroid biosynthesis in prostate cancer. Clin Cancer Res 19(13): 3353-3359
12. Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman Jr. OB, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 13(10): 983-992
13. Friedlander TW, Roy R, Tomlins SA, Ngo VT, Kobayashi Y, Azameera A, Rubin MA, Pienta KJ, Chinnaiyan A, Ittmann MM, Ryan CJ, Paris PL. (2012). Common structural and epigenetic changes in the genome of castration-resistant prostate cancer. Cancer Res 72(3): 616-625
14. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC, Asangani IA, Ateeq B, Chun SY, Siddiqui J, Sam L, Anstett M, Mehra R, Prensner JR, Palanisamy N, Ryslik GA, Vandin F, Raphael BJ, Kunju LP, Rhodes DR, Pienta KJ, Chinnaiyan AM, Tomlins SA. (2012). The mutational landscape of lethal castration-resistant prostate cancer. Nature 487(7406): 239-243
15. Karantanos T, Corn PG, Thompson TC. (2013). Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32(49): 5501-5511
16. Lin D, Gout PW, Wang Y. (2013). Lessons from in-vivo models of castration resistant prostate cancer. Curr Opin Urol 23(3): 214-219
17. Logothetis CJ, Gallick GE, Maity SN, Kim J, Aparicio A, Efstathiou E, Lin SH. (2013). Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer. Cancer Discov 3(8): 849-861
18. Loriot Y, Bianchini D, Ileana E, Sandhu S, Patrikidou A, Pezaro C, Albiges L, Attard G, Fizazi K, De Bono JS, Massard C. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 24(7): 1807-1812
19. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, Fleisher M, Sander C, Sawyers CL, Scher HI. (2012). Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 72(23): 6142-6152
20. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. (2013). Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447): 108-112
21. Noonan KL, North S, Bitting RL, Armstrong AJ, Ellard SL, Chi KN. (2013). Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 24(7): 1802-1807
22. O'Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, Harland S, Robbins A, Halbert G, Nutley B, Jarman M. (2004). Hormonal impact of the 17alpha-hydroxylase/C (17, 20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer 90(12): 2317-2325
23. Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368(2): 138-148
24. Ryan CJ, Smith MR, Fizazi K, Saad F, Mulders PF, Sternberg CN, Miller K, Logothetis CJ, Shore ND, Small EJ, Carles J, Flaig TW, Taplin ME, Higano CS, de Souza P, de Bono JS, Griffin TW, De Porre P, Yu MK, Park YC, Li J, Kheoh T, Naini V, Molina A, Rathkopf DE. (2015). Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 16(2): 152-160
25. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A. (2008). Prostate Cancer Clinical Trials Working Group. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26(7): 1148-1159
26. Schrader AJ, Boegemann M, Ohlmann Ch, Schnoeller TJ, Krabbe LM, Hajili T, Jentzmik F, Stoeckle M, Schrader M, Herrmann E, Cronauer MV. (2014). Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65(1): 30-36
27. Schwarzenbach H, Alix-Panabières C, Müller I, Letang N, Vendrell JP, Rebillard X, Pantel K. (2009). Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer. Clin Cancer Res 15(3): 1032-1038
28. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL. (2010). Integrative genomic profiling of human prostate cancer. Cancer Cell 18(1): 11-22
29. Tsao CK, Galsky MD, Small AC, Yee T, Oh WK. (2012). Targeting the androgen receptor signalling axis in castration-resistant prostate cancer (CRPC). BJU Int 110(11): 1580-1588
30. Waterman MR, Keeney DS. (1992). Genes involved in androgen biosynthesis and the male phenotype. Horm Res 38(5-6): 217-221